InvivoSciences, Inc. and Torrey Pines Institute for Molecular Studies (TPIMS) announced today they will be working together to accelerate drug discovery in cardiac disease.

“We are especially proud and pleased to establish a long-term relationship with the internationally recognized Torrey Pines Institute,” Ayla Annac, co-founder and CEO of InvivoSciences, said in a statement, “and recognize its entrepreneurial spirit and commitment to accelerate drug discovery.”

The two companies will work together to screen Torrey Pines’ collection of compounds in InvivoSciences’ assay system. This will be aided by Torrey Pines’ methods for the rapid synthesis and screening of compound libraries containing up to billions of compounds.

Financial terms were not released.